mometasone furoate nasal spray + placebo nasal spray

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Nasal Obstruction

Conditions

Nasal Obstruction, Adenoids Hypertrophy, Adenoidectomy

Trial Timeline

May 1, 2006 → Oct 1, 2009

NCT ID

NCT00553891

About mometasone furoate nasal spray + placebo nasal spray

mometasone furoate nasal spray + placebo nasal spray is a approved stage product being developed by Organon for Nasal Obstruction. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00553891. Target conditions include Nasal Obstruction, Adenoids Hypertrophy, Adenoidectomy.

What happened to similar drugs?

7 of 20 similar drugs in Nasal Obstruction were approved

Approved (7) Terminated (2) Active (12)

✅Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved

✅Budesonide NasalJohnson & JohnsonApproved

✅mometasone furoateMerckApproved

✅Dupilumab SAR231893SanofiApproved

✅DupilumabSanofiApproved

✅Dupilumab + Omalizumab + PlaceboSanofiApproved

✅Dupilumab Prefilled SyringeRegeneron PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00553891	Approved	Withdrawn	May 1, 2006	Oct 1, 2009	Nasal Obstruction
NCT03861559	Phase 3	Completed	Mar 30, 1994	Jul 7, 1994	Rhinitis, Allergic, Seasonal

Competing Products

20 competing products in Nasal Obstruction

See all competitors

Product	Company	Stage	Hype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone	Eli Lilly	Phase 2	31
Rabeprazole 20 mg twice a day for 90-day period treatment	Eisai	Phase 2	35
High dose of methotrexate + Gemcitabine + Pegaspargase + Dexamethasone	Eli Lilly	Phase 2	31
LY3650150 + Placebo + Standard therapy for INCS	Eli Lilly	Phase 3	47
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mg	Johnson & Johnson	Approved	43
xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic	Johnson & Johnson	Phase 3	40
Budesonide Nasal	Johnson & Johnson	Approved	47
Diphenhydramine hydrochloride	Johnson & Johnson	Phase 1	29
SHR-1210	Jiangsu Hengrui Medicine	Phase 2	31
Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroid	AstraZeneca	Phase 3	40
Benralizumab 30 mg + Matched placebo	AstraZeneca	Phase 3	32
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone Furoate	AstraZeneca	Phase 3	40
Benralizumab + Placebo	AstraZeneca	Phase 3	40
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	42
mometasone furoate	Merck	Approved	35
Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo	Novartis	Phase 3	40
Omalizumab + Placebo	Novartis	Phase 2	35
Omalizumab + Placebo	Roche	Phase 3	40
Omalizumab + Placebo	Roche	Phase 3	40
Omalizumab + Placebo	Roche	Phase 3	40